Company: IMRX
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001790340-25-000104
Chunk: 391

Company: Immuneering Corp
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 8
Chunk 391
---
 costs, offset by minor increases in stock-based compensation expense, facilities and other expenses, in the aggregate. 

30

General and Administrative

The following table summarizes the components of general and administrative expenses for the periods indicated:

Six Months Ended June 30,Change20252024$%(in thousands, except percentages)Employee-related costs$4,271 $4,243 $28 0.7 %Stock-based compensation expense1,874 1,891 (17)(0.9)%Professional fees1,569 1,356 213 15.7 %Facilities and other allocated expenses126 156 (30)(19.2)%Other461 724 (263)(36.3)%Total general and administrative$8,301 $8,370 $(69)(0.8)%

General and administrative expenses decreased by approximately $69 thousand, or 0.8%, to approximately $8.3 million for the six months ended June 30, 2025 compared to approximately $8.4 million for the six months ended June 30, 2024. The decrease of approximately $69 thousand was primarily due to decreased stock-based compensation expense of approximately $17 thousand, a decrease of $30 thousand for facilities and other allocated expenses, and decreased other expenses of $0.3 million, offset by an increase in professional fees incurred for accounting, auditing, legal and tax services of approximately $0.2 million, and an increase in employee-related costs of $28 thousand.

Amortization of Intangible Asset

Amortization of intangible asset was $14,633 for the six months ended June 30, 2025, and 2024. This amortization is related to the technology acquired for the BioArkive acquisition completed in December 2021.

Other Income (Expense)

Interest income decreased by approximately $0.9 million for the six months ended June 30, 2025, compared to the six months ended June 30, 2024, driven primarily by lower interest rates and a lower total cash balance.

There was no other income for the six months ended June 30, 2025, compared to $0.2 million for the six months ended June 30, 2024. This was primarily a result of there being no marketable securities as of June 30, 2025 and December 31, 2024, respectively.

Liquidity and Capital Resources

Sources of Liquidity

We finance our operations